MDS Anemia - EPO/GCSF Response

Identify those with MDS likely to respond to stem-cell factors.

The global unit selector only affects unanswered questions
1.Serum Erythropoietin?
2.Transfusion needs?
Created by

1. Serum Erythropoietin?

Created by
0/2 completed

About this Calculator

In general, treatment with erythropoietin (EPO) may improve anemia in about 15-20% of patients with myelodysplastic syndromes (MDS). The combination of EPO and granulocyte colony-stimulating factor (GCSF) may improve response rates to ~40%. This predictive model uses two variables (serum EPO and transfusion need) to identify those who are most likely to respond to these stem-cell factors. The model was developed and validated predominantly in patients with low-risk MDS. Response is defined as a 100% reduction in RBC transfusion need or an increase in hemoglobin level by at least 1.5 g/L.

Legal Notices and Disclaimer

© 2020 QxMD Software Inc., all rights reserved. No part of this service may be reproduced in any way without express written consent of QxMD. This information should not be used for the diagnosis or treatment of any health problem or disease. This information is not intended to replace clinical judgment or guide individual patient care in any manner. Click here for full notice and disclaimer.